Adverse events associated with Aveir TM VR leadless pacemaker: A Food and Drug Administration MAUDE database study
Journal of Cardiovascular Electrophysiology · 2023-06 · 34 (6) · 1469-1471
DOI: 10.1111/jce.15932 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cardiovascular Electrophysiology, online erschienen am 20.05.2023. Verfasst von Jalaj Garg und 6 weiteren Autor:innen. Beteiligte Einrichtung: Cardiac Arrhythmia Service, Loma Linda University Health, Loma Linda, California, USA. Hauptthemen laut MEDLINE: Pericardial Effusion, Pacemaker, Artificial, Virtual Reality. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 5 Literaturangaben.
Themen: Patientensicherheit
Abstract (Originalsprache)
Background
Leadless pacemaker (LP) offers an innovative approach for treating bradyarrhythmia, thus avoiding pacemaker pocket and lead‐related complications. The Food and Drug Administration (FDA) has recently approved the Aveir™ leadless pacing system (screw‐in type LP).
Methods
We queried the FDA MAUDE database to study the safety profile and assess the types of complications with this relatively novel device technology. A MAUDE database search was conducted on January 20, 2023, for reports received post‐FDA approval to capture all adverse events.
Results
A total of 98 medical device report were reported for Aveir™ LP. After excluding duplicate, programmer‐related, or introducer‐sheath‐related entries ( n = 34), 64 entries were included. The most commonly encountered problem was high threshold/noncapture (28.1%, 18 events), followed by stretched helix (17.2%, 11 events) and device dislodgement (15.6%, ten events—5 intraprocedural, while 5 in the postoperative Day 1). Other reported events included high impedance (14.1%, nine events), sensing issues (12.5%, eight events), bent/broken helix (7.8%, five events), premature separation (4.7%, three events), interrogation problem (3.1%, two events), low impedance (3.1%, two events), premature battery depletion (1.6%, one event) and inadvertent MRI mode switch (1.6%, one event) and miscellaneous (15.6%, n = 10). There were eight serious patient injury events—pericardial effusion requiring pericardiocentesis (7.8%, five events) due to cardiac perforation that resulted in two deaths (3.1%) followed by sustained ventricular arrhythmias (4.6%, n = 3).
Conclusion
In our study assessing the real‐world safety profile of the Aveir™ LP, serious adverse events have been reported—life‐threatening ventricular arrhythmias, pericardial effusion, device explantation/reimplantation, and death.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cardiac Arrhythmia Service, Loma Linda University Health, Loma Linda, California, USA.
- Cardiac Arrhythmia Service, MercyOne Siouxland Heart and Vascular Center, Sioux City, Iowa, USA.
- Helmsley Electrophysiology Center, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
- Kansas City Heart Rhythm Institute and Research Foundation, Kansas City, Kansas, USA.
ORCID-Profile: Jalaj Garg, Kuldeep Shah, Dhanunjaya Lakkireddy
Zitieren
APA
Garg, J., Shah, K., Bhardwaj, R., Contractor, T., Mandapati, R., Turagam, M. K., & Lakkireddy, D. (2023). Adverse events associated with Aveir TM VR leadless pacemaker: A Food and Drug Administration MAUDE database study. Journal of Cardiovascular Electrophysiology, 34(6), 1469-1471. https://doi.org/10.1111/jce.15932
Vancouver
Garg J, Shah K, Bhardwaj R, Contractor T, Mandapati R, Turagam MK, et al. Adverse events associated with Aveir TM VR leadless pacemaker: A Food and Drug Administration MAUDE database study. Journal of Cardiovascular Electrophysiology. 2023;34(6):1469-1471. doi:10.1111/jce.15932
BibTeX
@article{Garg2023,
author = {Garg, Jalaj and Shah, Kuldeep and Bhardwaj, Rahul and Contractor, Tahmeed and Mandapati, Ravi and Turagam, Mohit K and Lakkireddy, Dhanunjaya},
title = {Adverse events associated with Aveir TM VR leadless pacemaker: A Food and Drug Administration MAUDE database study},
journal = {Journal of Cardiovascular Electrophysiology},
year = {2023},
volume = {34},
number = {6},
pages = {1469--1471},
doi = {10.1111/jce.15932}
}
EUVIMED